Examining your relationship with CROs

Today we welcome another regular contributor to our Industry Voices column. Stephanie Wells is the Corporate Senior Vice President, Marketing and Chief Marketing Officer at Charles River Laboratories, a U.S.-based CRO with more than 9,000 employees worldwide. Wells has over twenty-five years of healthcare business experience, and has previously worked at Prior Ortho-Clinical Diagnostics (a Johnson & Johnson company) and Bayer Diagnostics.

Wells' executive position at a leading CRO has given her insight into how biotech and pharmaceutical companies can maximize their relationships with CROs. This changing healthcare landscape, she says, is the driving force behind a collaborative evolution within the industry, transforming traditional pharma-CRO relationships. To get Well's advice, scroll down or click here to read her article on getting the most from your CRO. - Maureen

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.